Overview of breast cancer collaborative stage data items-their definitions, quality, usage, and clinical implications: A review of seer data for 2004-2010

Cancer

Volumn 120, Issue S23, 2014, Pages 3771-3780

  Howlader, Nadia ^a   Chen, Vivien W ^b   Ries, Lynn A G ^a,c   Loch, Michelle M ^d   Lee, Richard ^e   DeSantis, Carol ^f   Lin, Chun Chieh ^f   Ruhl, Jennifer ^a   Cronin, Kathleen A ^a  

^a Cancer Control and Population Sciences   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c The Emmes Company   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f AMERICAN CANCER SOCIETY   (United States)

Author keywords

AJCC; Breast cancer; Collaborative stage; Prognostic; Site specific factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR ALPHA;

AXILLARY LYMPH NODE; BLOOM RICHARDSON SCORE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CHROMOGENIC IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; REVIEW; SCORING SYSTEM; TUMOR VOLUME; BREAST TUMOR; COHORT ANALYSIS; FEMALE; INFLAMMATORY BREAST CANCER; LUNG CARCINOMA; LYMPH NODE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; TRENDS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; LYMPH NODES; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SEER PROGRAM;

EID: 84911942145     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29059     Document Type: Review

References (29)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed August 5, 2013
3. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:408-418
4. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-357
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312
6. Carlson R, Allred D, Anderson B, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122-192
7. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th Ed. Chicago: Springer-Verlag; 2002.
8. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th Ed. Chicago: Springer-Verlag; 2010
9. Perou C, Jeffrey S, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999;96:9212-9217
10. Collaborative Stage Data Collection System Manual. Available at: http://web2.facs.org/cstage0204/breast/Breastschema.html. Accessed January 7, 2014
11. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Site Recode. Available at: http://seer.cancer.gov/siterecode/. Accessed August 16, 2013
12. Fritz A, Jack A, Parkin DM, et al. International Classification of Diseases for Oncology. 3rd Ed. Geneva, Switzerland: World Health Organization; 2000
13. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359-377
14. Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions, version 01.04.00. Jointly published by American Joint Committee on Cancer (Chicago, IL) and U.S. Department of Health and Human Services (Bethesda, MD), 2004. NIH Publication Number 04-5496. Incorporates updates through September 8, 2006. Available at: https://cancerstaging.org/references-tools/deskreferences/Pages/ default.aspx. Accessed January 7, 2014
15. Howlader N, Noone AM, Yu M, Cronin KA. Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol. 2012;176:347-356
16. Adamo MB JC, Ruhl JL, Dickie, LA, eds. 2013 SEER Program Coding and Staging Manual. Bethesda, MD: National Cancer Institute; 2013. NIH Pub. No. 13-5581
17. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103:1397-1402
18. DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20:733-739
19. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72
20. Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010;10:228
21. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721-1728
22. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295: 2492-2502
23. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104:1094-1101
24. Keegan TH, Derouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 2012;14:R55
25. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010;12:R99
26. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15:593-602
27. Reichman ME, Altekruse S, Li CI, et al. Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries. Cancer Epidemiol Biomarkers Prev. 2010;19:144-147
28. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint HER2 and hormone receptor status. J Natl Cancer Inst. 2014;105:1584-1598
29. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-1608.